Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-Analysis of randomized controlled trials

Medical Science Monitor

Volumn 17, Issue 8, 2011, Pages

  Ji, Xi Qing ^a   Ruan, Xin Jian ^a   Chen, Hong ^a   Chen, Gang ^a   Li, Shi Yong ^a   Yu, Bo ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Advanced hepatocellular carcinoma; Meta analysis; Octreotide

Indexed keywords

OCTREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE;

ADVANCED CANCER; CANCER SURVIVAL; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 80051543075     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881892     Document Type: Review

References (35)

1. Parkin DM, Bray F, Ferlay J et al: Estimating the world cancer burden: Globocan 2000. Int J Cancer, 2001; 94: 153-56
2. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet, 2003; 362: 1907-17
3. Shi J, Zhu L, Liu S et al: A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer, 2005; 92: 607-12
4. El-Serag HB, Davila JA, Petersen NJ et al: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med, 2003; 139: 817-23
5. Cho YK, Kim JK, Kim MY et al: Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology, 2009; 49: 453-59
6. Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008; 48: 520-37
7. Llovet JM, Ricci S, Mazzaferro V et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008; 359: 378-90
8. Cheng AL, Kang YK, Chen ZD et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009; 10: 25-34
9. Liu HL, Huo L, Wang L: Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin, 2004; 25: 1380-86
10. Xidakis C, Kolios G, Valatas V et al: Effect of octreotide on apoptosis-related proteins in rat Kupffer cells: a possible anti-tumour mechanism. Anticancer Res, 2004; 24: 833-41
11. Lamberts SW, van der Lely AJ, de Herder WW et al: Octreotide. New Engl J Med, 1996; 334: 246-54
12. Samonakis DN, Notas G, Christodoulakis N et al: Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci, 2008; 53: 2359-65
13. Slijkhuis WA, Stadheim L, Hassoun ZM et al: Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol, 2005; 39: 333-38
14. Kouroumalis E, Skordilis P, Thermos K et al: Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut, 1998; 42: 442-47
15. Samonakis DN, Moschandreas J, Arnaoutis T et al: Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep, 2002; 9: 903-7
16. Yuen MF, Poon RT, Lai CL et al: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology, 2002; 36: 687-91
17. Becker G, Allgaier HP, Olschewski M et al: Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology, 2007; 45: 9-15
18. Barbare JC, Bouche O, Bonnetain F et al: Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer, 2009; 45: 1788-97
19. Guo TK, Hao XY, Ma B et al: Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol, 2009; 135: 1685-92
20. Jia WD, Zhang CH, Xu GL et al: Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials. Hepatogastroenterology, 2010; 57: 292-99
21. Jadad AR, Moore RA, Carroll D et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996; 17: 1-12
22. Kjaergard LL, Villumsen J, Gluud C: Reported methodologic quality and discrepancies between large and small randomized trials in metaanalyses. Ann Intern Med, 2001; 135: 982-89
23. Moher D, Pham B, Jones A et al: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet, 1998; 352: 609-13
24. Farooqi JI, Farooqi RJ: Efficacy of octreotide in cases of inoperable hepatocellular carcinoma: a clinical trial. J Coll Physicians Surg Pak, 2000; 10: 258-60
25. Wu P, Gu XY, Jiang Z et al: Efficacy of octreotide in advanced hepatocellular carcinoma: A clinical trial. Chin J Hepatobiliary Surg, 2001; 7: 766-68
26. Yang MN, Xiao B, Wang XL et al: Effects of octreotide in elderly patients with advanced primary hepatic cancer. J Clin Med in Pract, 2003; 7: 302-4
27. Zhang L, Jiang Z, Li SY et al: Clinical Study of octreodide for advanced primary Liver Cancer. Chin Clin Oncol, 2004; 9: 514-17
28. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K et al: Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol, 2007; 13: 3164-70
29. Ou SQ, Chen ZQ, Ma YL: Clinical study of octreotide for advanced hepatocellular carcinoma. Hainan Med J, 2007; 18: 19-20
30. Zhang B, Xu F: The clinical observation of octreotide in the treatment of 45 patients with advanced primary liver carcinoma. J Basic Clin Oncol, 2010; 23: 52-54
31. El-Din HG, Ghafar NA, Saad NE et al: Relationship between codon 249 mutation in exon 7 of p53 gene and diagnosis of hepatocellular carcinoma. Arch Med Sci, 2010; 6: 348-55
32. Bassiouny AE, Abou-Shousha T, Moussa M et al: Hepatic mRNA expression of histone (H3): an early predictor of tumorgenic changes in chronic hepatitis C. Arch Med Sci, 2009; 5: 506-12
33. Bassiouny AE, El-Hassan SA, Moussa M et al: Down-regulation of intrahepatic CD16+ and CD56+ immune cells in chronic Hepatitis C virus infection and HCV-related hepatocellular carcinoma. Arch Med Sci, 2009; 5: 321-28
34. Cebon J, Findlay M, Hargreaves C et al: Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer, 2006; 95: 853-61
35. Reynaert H, Rombouts K, Vandermonde A et al: Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut, 2004; 53: 1180-89